Authors

Latest:

Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Gautam Jayram, MD

Latest:

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Nicholas Stollenwerk, MD

Latest:

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Lori J. Wirth, MD, Massachusetts General Hospital

Latest:

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Shannon L. Maude, MD, PhD

Latest:

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Rami Manochakian, MD

Anita Rijneveld, MD

Latest:

Dr Rijneveld on the Addition of Blinatumomab to Prephase and Consolidation Therapy in B-ALL

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Rondell Graham, MBBS

Latest:

Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Sarah Sammons, MD, Duke Cancer Institute

Latest:

Targeting the PI3K Pathway in HR+/HER2- MBC

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

Russell Langan, MD

Latest:

RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

Mark G. Kris, MD

Latest:

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Shipra Gandhi, MD

Latest:

Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).

Hiromichi Shirasu, MD

Latest:

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Kevin M. Kalinsky, MD, Columbia University Medical Center

Latest:

Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast Cancer

Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.

Craig Jones, MBChB

Latest:

Dr Jones on Clinical Fracture Incidence in mHSPC

Craig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.

Arnon Kater, MD, PhD

Latest:

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Rebecca L. Porter, MD, PhD

Latest:

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Narjust Florez (Duma), MD

Latest:

Dana-Farber Cancer Institute and the Florez Laboratory Set to Launch Innovative Pregnancy and Lung Cancer Registry

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Nathalie Albert, MD

Latest:

Q&A: Final Questions on Glioblastoma and Neuroimaging

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Latest:

Academic Perspectives for the Management of HPV-Positive HNSCC

Panelists discuss how human papillomavirus (HPV)–related tumors vary in aggressiveness, with HPV-positive head and neck squamous cell carcinoma (HNSCC) presenting unique challenges. Key treatment hurdles include tumor heterogeneity, resistance development, and optimizing de-escalation strategies while maintaining efficacy.